Jackson Square Partners LLC Has $841,000 Position in Sight Sciences, Inc. (NASDAQ:SGHT)

Jackson Square Partners LLC reduced its stake in Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) by 74.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 230,997 shares of the company's stock after selling 687,062 shares during the period. Jackson Square Partners LLC owned approximately 0.46% of Sight Sciences worth $841,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in SGHT. KCK LTD. purchased a new position in shares of Sight Sciences in the fourth quarter valued at $15,925,000. Geode Capital Management LLC boosted its position in Sight Sciences by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 784,129 shares of the company's stock valued at $4,941,000 after buying an additional 12,709 shares during the last quarter. State Street Corp boosted its position in Sight Sciences by 17.4% in the 3rd quarter. State Street Corp now owns 646,776 shares of the company's stock valued at $4,075,000 after buying an additional 95,843 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Sight Sciences by 4.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 268,250 shares of the company's stock worth $976,000 after acquiring an additional 11,259 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its position in shares of Sight Sciences by 46.3% during the third quarter. Jacobs Levy Equity Management Inc. now owns 207,893 shares of the company's stock worth $1,310,000 after acquiring an additional 65,767 shares during the last quarter. 55.51% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Citigroup lowered their target price on Sight Sciences from $4.60 to $3.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Lake Street Capital dropped their target price on Sight Sciences from $3.00 to $2.50 and set a "hold" rating on the stock in a research report on Thursday, March 6th. Stifel Nicolaus dropped their price objective on shares of Sight Sciences from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Piper Sandler lowered their target price on shares of Sight Sciences from $5.50 to $3.50 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Finally, UBS Group decreased their price objective on shares of Sight Sciences from $5.50 to $5.00 and set a "buy" rating for the company in a report on Monday, January 27th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $3.83.

Insiders Place Their Bets

In other Sight Sciences news, CEO Paul Badawi sold 24,819 shares of Sight Sciences stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $2.92, for a total value of $72,471.48. Following the completion of the sale, the chief executive officer now directly owns 5,676,331 shares in the company, valued at $16,574,886.52. The trade was a 0.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Manohar K. Raheja bought 10,000 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was acquired at an average cost of $2.73 per share, with a total value of $27,300.00. Following the completion of the transaction, the executive vice president now directly owns 145,000 shares of the company's stock, valued at approximately $395,850. This represents a 7.41 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 63,014 shares of company stock valued at $197,295 in the last three months. Insiders own 28.90% of the company's stock.

Sight Sciences Stock Down 6.9 %

Shares of NASDAQ SGHT traded down $0.19 during mid-day trading on Friday, reaching $2.55. The company had a trading volume of 82,035 shares, compared to its average volume of 211,963. The stock has a fifty day moving average of $2.73 and a two-hundred day moving average of $3.99. Sight Sciences, Inc. has a 12-month low of $2.17 and a 12-month high of $8.45. The company has a market capitalization of $130.90 million, a price-to-earnings ratio of -2.50 and a beta of 2.52. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last released its earnings results on Wednesday, March 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.01). Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The company had revenue of $19.07 million during the quarter, compared to analysts' expectations of $18.98 million. During the same quarter in the previous year, the company earned ($0.22) EPS. As a group, equities research analysts expect that Sight Sciences, Inc. will post -0.99 EPS for the current year.

Sight Sciences Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.